STXK - ETF AI Analysis
Top Page
Strive 2000 ETF (STXK)
STXK’s rating suggests it is a reasonably solid but somewhat mixed ETF, with notable strengths offset by meaningful risks. Strong contributors like Qualys and InterDigital support the fund with robust profitability, cash flow, and positive earnings call sentiment, while several other holdings show good growth and strategic initiatives but struggle with profitability, cash flow, or valuation. The main risk is that many top positions face ongoing financial and technical challenges, creating a portfolio where future growth potential is balanced by higher volatility and execution risk.
STXK vs. SPDR S&P 500 ETF (SPY)
- AUM
- 78.50M
- Region
- North America
- Expense Ratio
- 0.18%
- Beta
- 0.95
- Issuer
- Strive
- Inception Date
- Nov 10, 2022
- Dividend Yield
- 1.17%
- Asset Class
- Equity
- Index Tracked
- Bloomberg US 600 Index - Benchmark TR Gross
STXK Summary
Strive 2000 ETF (STXK) is a fund that focuses on small U.S. companies and follows the Bloomberg US 600 Index. It spreads your money across many industries, including technology, financials, and healthcare, so you’re not betting on just one sector. The fund holds fast-growing names like Elastic and GitLab, aiming to capture the potential growth of smaller companies that could become tomorrow’s leaders. This ETF may appeal to investors looking for long-term growth and diversification beyond large, well-known stocks. A key risk is that small-cap stocks can be more volatile, so the price can move up and down more sharply than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.18%, which means you’ll pay about $1.80 per year for every $1,000 invested. That’s lower than the average stock ETF because it’s passively managed and tracks an index rather than paying for frequent trading or expensive research.
What would affect this ETF?
STXK could benefit if the U.S. economy grows steadily, as small-cap companies in technology, industrials, and consumer cyclical sectors often see faster expansion in good times, and its broad diversification across many industries helps spread risk. On the downside, higher interest rates, economic slowdowns, or tighter regulations on tech and health care could hurt smaller U.S. companies like its top holdings in software, biotech, and materials, which tend to be more sensitive to borrowing costs and business cycles.
STXK Top 10 Holdings
STXK leans heavily into U.S. small-cap growth, with a clear tilt toward tech and innovative healthcare names. Cybersecurity and software players like Qualys, GitLab, Elastic, and SentinelOne have been rising, giving the fund much of its recent spark. On the flip side, hardware-focused FormFactor and distributor Avnet have seen more mixed, sometimes lagging action, occasionally acting as a speed bump. Biotech and genomics names such as Twist Bioscience and 10x Genomics add punchy upside but also volatility, making this a domestically focused, high-beta bet on tomorrow’s niche leaders.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TWST | Twist Bioscience | 0.38% | $298.84K | $9.24B | 374.32% | 43Neutral |
 ESTC | Elastic | 0.36% | $284.08K | $9.59B | 1.30% | 65Neutral |
 S | SentinelOne | 0.35% | $273.09K | $8.04B | 39.24% | 61Neutral |
 CLF | Cleveland-Cliffs | 0.35% | $278.44K | $8.07B | 20.22% | 54Neutral |
 IDCC | InterDigital | 0.35% | $278.16K | $8.08B | -19.14% | 76Outperform |
 TXG | 10x Genomics | 0.33% | $255.94K | $8.51B | 405.39% | 60Neutral |
 QLYS | Qualys | 0.33% | $257.53K | $7.28B | 73.99% | 78Outperform |
 GTLB | Gitlab | 0.33% | $256.87K | $8.72B | 12.62% | 62Neutral |
 CROX | Crocs | 0.34% | $264.21K | $7.02B | 103.10% | 63Neutral |
 ANF | Abercrombie Fitch | 0.31% | $244.30K | $6.68B | 149.48% | 78Outperform |
STXK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXK, the sentiment is Positive. The current price of 37.54 is above the 20-day moving average (MA) of 36.43, above the 50-day MA of 36.83, and above the 200-day MA of 36.37, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 61.81 is Neutral, neither overbought nor oversold. The STOCH value of 73.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXK.
STXK Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| STXK | $37.54 | $39.00(3.89% Upside) | $78.50M | 0.18% | 65Neutral |
 RUSC | $37.24 | $50.03(34.32% Upside) | $84.25M | 0.64% | 64Neutral |
 AIMS | $27.51 | $34.58(25.68% Upside) | $83.19M | 0.75% | 65Neutral |
 BKSE | $43.69 | $52.92(21.15% Upside) | $83.07M | 0.04% | 65Neutral |
 SYZ | $29.75 | $36.71(23.41% Upside) | $60.79M | 0.61% | 66Neutral |
 ROSC | $56.55 | $64.04(13.25% Upside) | $49.85M | 0.34% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| STXK | Strive 2000 ETF | 37.54 | 5.40 | 16.78% | |
| RUSC | US Small Cap Equity Active ETF | 37.24 | 7.23 | 24.09% | |
| AIMS | Acuitas Small Cap Active ETF | 27.51 | 2.33 | 9.26% | |
| BKSE | BNY Mellon US Small Cap Core Equity ETF | 43.69 | 7.85 | 21.91% | |
| SYZ | Lazard US Systematic Small Cap Equity ETF | 29.75 | 5.87 | 24.59% | |
| ROSC | Hartford Multifactor Small Cap ETF | 56.55 | 12.52 | 28.43% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.